{"filings":[{"id":93192,"accession_number":"0001193125-26-142106","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"VivoSim prices up to $4M public offering, closes initial $3M tranche","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial closing raised $3M at $1.14/share; 286,557 shares + 2,345,022 pre-funded warrants sold.","Common warrants issued at 150% coverage, exercise price $1.71, expire 5 years from issuance.","Second $1M tranche contingent on stock price >$1.43 and avg daily volume >$100K.","Net proceeds ~$2.5M for working capital, R&D, and general corporate purposes.","Joseph Gunnar & Co. placement agent with 7.5% cash fee and 131,579 placement agent warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120883,"accession_number":"0001193125-25-324794","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"VivoSim Labs announces results of 2025 annual meeting; elects directors and ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Douglas Jay Cohen and David Gobel elected as Class II directors with 212,079 and 212,420 votes For, respectively.","Stockholders ratified Rosenberg Rich Baker Berman P.A. as independent auditor for FY2026 with 97.91% approval.","Advisory vote on executive compensation approved non-bindingly with 89.97% of votes cast (193,240 For, 21,542 Against).","Stockholders chose a one-year frequency for future advisory votes on executive compensation, with 97.17% voting for one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137482,"accession_number":"0000950170-25-108447","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"VivoSim Labs appoints Tony Lialin as Chief Commercial Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tony Lialin appointed CCO effective Aug 11, 2025; leads go-to-market strategy for NAMkind liver/intestine 3D models.","Annual salary $360,000, sign-on bonus $10,000, target bonus up to 40% of base salary.","Granted option to purchase 40,000 shares vesting over 4 years (25% cliff at 1 yr, then quarterly).","Company cites global liver/GI in-vitro market at $641M in 2024, U.S. share 50.8% ($325M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154828,"accession_number":"0000950170-25-063979","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"VivoSim Labs regains compliance with Nasdaq minimum equity and bid price rules","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On April 30, 2025, Nasdaq confirmed VivoSim Labs demonstrated compliance with minimum $2.5M stockholders' equity and $1.00 bid price requirements.","Company had faced delisting after Q4 2024 equity of $364,000; Hearing Panel granted exception until April 15, 2025.","Nasdaq imposed a Mandatory Panel Monitor for one year per Listing Rule 5815(d)(4)(B) starting April 30, 2025.","Compliance avoids imminent delisting of VIVS common stock from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154827,"accession_number":"0000950170-25-057685","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["5.03","7.01","8.01","9.01"],"status":"ready","headline":"Organovo Holdings renames to VivoSim Labs, emerges from stealth to target FDA animal testing phase-out","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective April 24, 2025, Organovo Holdings changed its name to VivoSim Labs, Inc. with new ticker symbol VIVS on Nasdaq.","In conjunction with the name change, VivoSim issued a press release announcing emergence from stealth mode to provide NAM models for liver and intestinal toxicology.","The FDA announced on April 10, 2025 a plan to phase out animal testing requirements, representing a potential >$10B market opportunity for VivoSim's non-animal technologies.","VivoSim’s NAMkind liver model achieved industry-best correlation with known clinical failures, aiming to reduce clinical trial failures and cut drug development costs by 50%.","The company's NAMkind intestine models offer novel readouts for drug candidate selection, targeting reduction of patient side effects from chemotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154826,"accession_number":"0000950170-25-056974","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Organovo rebrands as VivoSim Labs, ticker changes to VIVS effective April 24","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Company to carry forward 3D bioprinting and legacy technology as VivoSim Labs, Inc.","Name change effective April 24, 2025; new Nasdaq ticker symbol 'VIVS' begins trading at market open.","No action required by existing stockholders; CUSIP number 68620A302 remains unchanged.","Common stock continues to list on Nasdaq Capital Market under the new name."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154825,"accession_number":"0000950170-25-048888","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Organovo reports ~$11.3M cash, expects to meet Nasdaq listing requirements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash and equivalents ~$11.3M as of March 31, 2025; Q4 net cash utilization ~$2.0M-$2.2M.","Stock closed above $1.00 minimum bid since March 21, 2025; company expects to meet continued listing criteria.","Hearings Panel granted exception until April 15, 2025 to demonstrate compliance with bid price and equity rules.","Believes it meets $2.5M stockholders' equity after $9M upfront from FXR asset sale to Eli Lilly.","Expects potential $5M milestone within 12 months from FXR program upon Phase 2 trial commencement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173341,"accession_number":"0000950170-25-045740","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Organovo closes FXR program sale to Lilly; expects reduced spend and runway into FY2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["FXR program sold to Lilly; upfront payments received with future milestone payments anticipated.","Overall expenditures expected to decrease due to elimination of FXR-related clinical, regulatory, and IP costs.","Cash runway projected through end of FY2026; additional milestone payments could extend runway.","Plans to leverage 3D human cellular IBD models to replicate FXR success with another therapeutic opportunity.","Full-year FY2025 financial results expected on or about June 6-10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173340,"accession_number":"0000950170-25-044801","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.01","5.02","8.01","9.01"],"status":"ready","headline":"Organovo closes sale of FXR program to Lilly for $10M upfront plus up to $50M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale of FXR program including lead asset FXR314 to Eli Lilly completed on March 25, 2025.","Upfront cash payment $10M; $9M paid at closing, $1M held in escrow for 15 months.","Potential milestone payments up to $50M contingent on development, regulatory, and commercial milestones.","Lilly assumes certain liabilities and will be responsible for all future clinical development of FXR314.","Director Vaidehi Joshi resigned March 21, 2025, effective immediately, with no disagreement with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173339,"accession_number":"0000950170-25-042903","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Organovo implements 1-for-12 reverse stock split to regain Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio 1-for-12, effective March 20, 2025, to combine every 12 shares into 1.","Trading on Nasdaq Capital Market on split-adjusted basis begins March 21, 2025 under ticker ONVO.","No fractional shares issued; cash paid in lieu based on March 19 closing price of common stock.","Board approved reverse split ratio on March 6, 2025 after shareholder authorization granted November 20, 2024.","Reverse split intended to cure Nasdaq minimum bid price deficiency for continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173338,"accession_number":"0000950170-25-041749","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Organovo announces 1-for-12 reverse stock split effective March 20, 2025 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-12 reverse stock split effective 5:00 p.m. ET on March 20, 2025; adjusted trading begins March 21.","Outstanding shares reduce from ~21.4M to ~1.8M; fractional shares paid in cash at March 19 closing price.","Approved by shareholders on Nov 20, 2024; board selected 1-for-12 ratio on March 6, 2025.","Intended to regain compliance with Nasdaq $1.00 minimum bid price for continued listing on Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173337,"accession_number":"0000950170-25-034181","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Organovo issues ~3M shares via warrant exercises and ATM sales, raising ~$2.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,967,144 shares of common stock from warrant exercises and at-the-market sales.","Gross proceeds expected to be approximately $2.3 million, before fees and commissions.","After issuance, total outstanding shares are 20,421,617.","Warrant shares registered under an effective shelf registration statement (May 8, 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173336,"accession_number":"0000950170-25-026097","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["1.01","3.01","8.01","9.01"],"status":"ready","headline":"Organovo sells FXR program to Eli Lilly for $10M upfront; faces Nasdaq delisting","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Lilly to buy Organovo's FXR program for $10M upfront ($9M at close, $1M escrow) + up to $50M in milestones.","Lead asset FXR314, an oral FXR agonist for IBD, to be advanced to Phase 2 by Lilly.","Organovo faces Nasdaq delisting: stockholders' equity of $364K as of Dec 31, 2024, below $2.5M minimum.","Hearing before Nasdaq panel scheduled Feb 27, 2025; company may pursue reverse stock split to regain bid price compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173335,"accession_number":"0000950170-25-006819","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Organovo receives Nasdaq delisting notice for bid price non-compliance; intends to appeal with reverse split plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Organovo on Jan 16, 2025 that it failed to regain compliance with $1 minimum bid price rule.","Company is not eligible for a second 180-day compliance period on The Nasdaq Capital Market.","Organovo intends to timely request a hearing, which will automatically stay any delisting pending a decision.","Hearing panel may grant an extension up to July 15, 2025; company plans to propose a reverse stock split.","Common stock continues to trade on Nasdaq under symbol ONVO pending the hearing outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190352,"accession_number":"0000950170-24-141323","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Organovo names Norman Staskey President and CFO; Tomas Hess resigns for retirement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tomas Hess resigned as President, CFO effective Dec 24, 2024 to pursue retirement; no disagreement on accounting policies.","Norman Staskey appointed President, CFO and Principal Financial Officer effective Dec 30, 2024, via Danforth Advisors consulting agreement.","Staskey is paid $450/hour under the Danforth Consulting Agreement; he also serves as CFO of Azitra, Inc.","Staskey brings M&A experience as company pursues potential strategic transactions with other pharma firms.","Amendment No. 6 to Consulting Agreement formalizes Staskey's services; prior CFO services were from Hess."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190351,"accession_number":"0000950170-24-129965","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Organovo shareholders approve reverse stock split (1:5-1:20) and 1.78M share equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split authorized at ratio 1-to-5 to 1-to-20, board discretion until Nov 20, 2025; 88.64% voted for.","2022 Equity Incentive Plan amended to add 1,775,000 shares; 89.41% approval.","Class I directors Alison Tjosvold Milhous and Vaidehi Joshi elected with ~92.4% and ~93.9% of votes cast, respectively.","Rosenberg Rich Baker Berman ratified as auditor for FY ending March 2025 (89.25% approval).","Advisory vote on named executive officer compensation passed with 92.30% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206847,"accession_number":"0000950170-24-094736","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Organovo grants Chairman Murphy options on ~1M shares at $0.5368, vesting over 3 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Time-based option for 574,923 shares vests 1/3 annually over 3 years subject to continued service.","Performance-based option for 431,193 shares vests upon achieving revenue, market cap, stock price, and strategic goals.","Additional 'True-Up Options' may be granted if equity financing closes by March 31, 2025, below specified dilution thresholds.","Options granted under 2022 Equity Incentive Plan, approved by Compensation Committee on August 4, 2024.","Exercise price set at $0.5368 per share; grant date is August 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206846,"accession_number":"0000950170-24-086026","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Organovo received Nasdaq delisting notice for bid price below $1 per share","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on July 18, 2024: closing bid price below $1 for 30 consecutive business days.","180-day compliance period granted until January 14, 2025 to regain bid price rule.","To regain compliance, closing bid must be at least $1 for ten consecutive business days.","Company may consider reverse stock split subject to stockholder approval if not cured.","Trading of ONVO common stock continues on Nasdaq Capital Market without immediate effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224128,"accession_number":"0000950170-24-058805","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Organovo prices $5.25M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 6.56M units at $0.80/unit; gross proceeds $5.25M before expenses.","Each unit includes one share (or pre-funded warrant) and one common warrant exercisable at $0.80 for 5 years.","Net proceeds ~$4.7M after expenses; expected close May 13, 2024.","Proceeds to be used for working capital, R&D, clinical trials, and general corporate purposes.","JonesTrading acted as exclusive placement agent; securities offered under effective S-1 registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224127,"accession_number":"0000950170-24-050906","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Organovo furnishes May 2024 corporate presentation; no specific financial data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted investor presentation on its website covering business overview and strategy.","Presentation includes forward-looking statements and is current as of May 1, 2024.","No material new information such as earnings, guidance, or clinical milestones were disclosed in the excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224126,"accession_number":"0000950170-24-046879","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Organovo issues 1.35M shares for ~$1.8M under ATM facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,349,778 shares between Feb 1 and Apr 19, 2024; gross proceeds of $1.8 million.","ATM facility with H.C. Wainwright and JonesTrading originally authorized up to $50 million.","Outstanding shares as of April 19, 2024: 11,391,102."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243473,"accession_number":"0000950170-24-011954","cik":1497253,"company_name":"VivoSim Labs, INC.","ticker":"VIVS","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Organovo presents FXR314 data in 3D models of Crohn's disease and ulcerative colitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FXR314, a clinical-stage FXR agonist, tested in human primary cell 3D models.","Data presented at Crohn's & Colitis Congress, Jan 25-27, 2024 in Las Vegas.","Presentation covers models for both Crohn's disease and ulcerative colitis.","Presentation current as of January 25, 2024; furnished as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3360000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}